Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -31.33% is 51% above its 5-year average of -64.55%, near the high end of its 5-year range (-78.50%–-31.33%).
44.78% above its 12-month average of -56.73%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.06%.
RETURN ON ASSETS (ROA)
-31.33%
RETURN ON ASSETS (ROA) AVG TTM
-56.73%
RETURN ON ASSETS (ROA) AVG 3Y
-59.49%
RETURN ON ASSETS (ROA) AVG 5Y
-64.55%
RETURN ON ASSETS (ROA) AVG 10Y
-53.37%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+44.78%
CURRENT VS 3Y AVG
+47.34%
CURRENT VS 5Y AVG
+51.46%
CURRENT VS 10Y AVG
+41.30%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.71%
median of 389 covered companies
CURRENT VS SECTOR MEDIAN
-32.14%
vs the sector median at left
Cibus, Inc.
Market Cap
$128.24M
Return on Assets (ROA)
-31.33%
TTM Avg
-56.73%
3Y Avg
-59.49%
5Y Avg
-64.55%
Market Cap
$129.14M
Return on Assets (ROA)
-87.44%
TTM Avg
-86.57%
3Y Avg
-87.06%
5Y Avg
-85.09%
Market Cap
$125.27M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
Market Cap
$134.74M
Return on Assets (ROA)
-6.07%
TTM Avg
-5.08%
3Y Avg
-4.92%
5Y Avg
-1.70%
Market Cap
$118.63M
Return on Assets (ROA)
-4.60%
TTM Avg
-3.66%
3Y Avg
-5.21%
5Y Avg
-1.02%
Market Cap
$118.02M
Return on Assets (ROA)
-72.42%
TTM Avg
-66.03%
3Y Avg
-45.57%
5Y Avg
-48.77%
Market Cap
$117.43M
Return on Assets (ROA)
-31.75%
TTM Avg
-34.00%
3Y Avg
-32.33%
5Y Avg
-29.29%
Market Cap
$116.59M
Return on Assets (ROA)
-128.96%
TTM Avg
-127.49%
3Y Avg
-112.64%
5Y Avg
-129.28%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cibus, Inc. (CBUS) | $128.24M | -31.33% | -56.73% | -59.49% | -64.55% |
| Entera Bio Ltd. (ENTX)vs › | $129.14M | -87.44% | -86.57% | -87.06% | -85.09% |
| enGene Holdings Inc. (ENGN)vs › | $125.27M | -1.70% | -35.34% | -51.03% | -36.99% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $134.74M | -6.07% | -5.08% | -4.92% | -1.70% |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $118.63M | -4.60% | -3.66% | -5.21% | -1.02% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | -72.42% | -66.03% | -45.57% | -48.77% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | -31.75% | -34.00% | -32.33% | -29.29% |
| Genelux Corporation (GNLX)vs › | $116.59M | -128.96% | -127.49% | -112.64% | -129.28% |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | -36.33% | -27.39% | -256.74% | -207.88% |
ROA
-31.3%
ROE
-663.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -41.66% |
| 2024-12-31 | -71.81% |
| 2023-12-31 | -49.16% |
| 2022-12-31 | -75.34% |
| 2021-12-31 | -78.50% |
| 2020-12-31 | -70.80% |
| 2019-12-31 | -44.96% |
| 2018-12-31 | -23.48% |
| 2017-12-31 | -36.00% |
| 2016-12-31 | -72.71% |
| 2015-12-31 | -22.65% |
